Skip to main content
BoF Logo

Agenda-setting intelligence, analysis and advice for the global fashion community.

Novo Nordisk Forecasts Sharp Revenue Drop in 2026

The maker of Wegovy and Ozempic has predicted a sharp drop in revenues this year, owing to a push by Donald Trump to lower US weight-loss drug prices, rising competition and the loss of key patent protections.
Ozempic, Victoza and Wegovy
Novo Nordisk has warned of “unprecedented” price pressures in 2026, in ‍sharp contrast to rival Eli Lilly's more ⁠upbeat outlook. (Getty Images)

Eli Lilly forecast 2026 profit above Wall Street estimates on Wednesday, betting on surging demand for its obesity drugs as the world’s most valuable drugmaker ⁠prepares to launch its oral weight-loss pill later this ⁠year.

Please sign in to ensure you can read our agenda-setting intelligence, analysis and advice. Or get in touch at support@businessoffashion.com if you experience difficulties.

© 2026 The Business of Fashion. All rights reserved. For more information read our Terms & Conditions

More from Beauty
Analysis and advice on the fast-evolving beauty business.

What Stops Beauty Shoppers From Buying More

Beauty brands must rethink upselling with smarter value plays, from curated bundles to jumbo sizes and subscriptions, to keep their customers from switching to the competition.


Can Mikayla Nogueira Sell Fragrance, Too?

The beauty influencer is hoping her 20 million-strong following can cut through the category’s oversaturation with Only Sunshine, a tropical scent launched with indie brand Snif.


Ulta Beauty Joins TikTok Shop

Ulta Beauty becomes the first US specialty beauty retailer to launch on TikTok Shop, making the case for partnership rather than competition with the platform’s beauty e-commerce business.


view more
Latest News & Analysis
Unrivalled, world class journalism across fashion, luxury and beauty industries.
VIEW MORE
Agenda-setting intelligence, analysis and advice for the global fashion community.
CONNECT WITH US ON